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ARTICLE OPEN
Inappropriate asthma therapy—a tale of two countries:
a parallel population-based cohort study
Manon Belhassen1, Anjan Nibber2, Eric Van Ganse1,3, Dermot Ryan4,5, Carole Langlois1, Francis Appiagyei5, Derek Skinner5,
Laurent Laforest1, Joan B Soriano2,6 and David Price2,7
Against recurrent controversies around the safety of short- and long-acting β2-agonists (SABA and LABA), and the National Review
of Asthma Deaths inquiry in the United Kingdom, we investigated the prevalence of inappropriate therapy in asthma. Our study
aimed to determine the prevalence of inappropriate use of asthma therapy in the United Kingdom and in France. Two interval,
parallel, population-based cohorts (2007 and 2013) were developed in each country by using the UK OPCRD and the French EGB
databases. Patients aged 6–40 years were studied over the 12-month period following inclusion, regarding overuse (⩾12 units) of
SABA, use of LABA without inhaled corticosteroids (ICS) and ⩾ 2-fold higher use of LABA compared with that of ICS. Overall, 39,743
UK and 4,910 French patients were included in 2007, and 14,036 and 5,657 patients, respectively, were included in 2013. UK adults
were more frequently exposed to SABA overuse compared with those in France in both periods, with an upward trend in the United
Kingdom (Po0.05). In 2013, LABA use without ICS occurred in 0.1% and 1.5% of United Kingdom and French adults, respectively.
Unbalanced use of LABA relative to ICS became marginal in both countries in 2013. Inappropriate use of therapy was less marked,
but present, in children. Inappropriate therapy remains a common issue in asthma. Based on our ﬁgures, it may be estimated that
4210,000 British and 4190,000 French asthmatics aged 6–40 years were inappropriately treated in 2013.
npj Primary Care Respiratory Medicine (2016) 26, 16076; doi:10.1038/npjpcrm.2016.76; published online 13 October 2016
INTRODUCTION
Potentially preventable factors have been identiﬁed in the
majority of asthma exacerbations and deaths.1 In addition, despite
widely disseminated guidance for asthma management,2
intensive research concerning asthma management in primary
care, novel drugs for treatment,3 and research on effectiveness,4
morbidity and mortality due to asthma (in all age categories)
remains unacceptably high throughout Europe and elsewhere,
with the recently updated ﬁgure of 334 million asthmatics
worldwide in 2012.5
Contributing factors include the inappropriate prescribing and
use of asthma medication. A recent report from the United
Kingdom, prepared by the National Review of Asthma Deaths,
aimed to identify avoidable risk factors and to make recommen-
dations for improving care and reducing the number of deaths.6
This report drew attention to the excessive prescribing of reliever
medication (39% of patients had been prescribed 412 short-
acting reliever inhalers in the year before they died), or the under-
prescribing of preventer medication; namely, 38% of patients were
issued with fewer than 4 and 80% with fewer than 12 preventer
inhalers in the previous year, and the inappropriate prescribing of
long-acting β2-agonist (LABA) bronchodilator inhalers (14% of
those who died were prescribed a single-component LABA
bronchodilator at the time of death and at least 3% of patients
were on LABA monotherapy without inhaled corticosteroid (ICS)
preventer treatment). Against this background, we investigated
asthma therapy in comparable populations of the United Kingdom
and France, to assess the prevalence of inappropriate use and to
identify changes over recent years (2007–2013).
RESULTS
In 2007, 39,743 UK patients were included in the cohort, with a
mean age of 23.7 years (27% children and 73% adults) and 53.2%
males. In 2013, 14,036 patients met our inclusion criteria, with a
mean age of 24.2 years (22% children and 78% adults) with
51.8% males.
In 2007, 4,910 French patients were studied. The cohort
included 50.8% males (33% children and 66% adults), with a
mean age of 22.1 years. In 2013, 5,657 patients were included
(35.5% children and 64.5% adults), with a mean age of 21.4 years
with 51.1% males (Table 1).
Inappropriate patterns of use
SABA overuse. Short-acting β2-agonist (SABA) overuse in 2013,
deﬁned as 12 prescriptions/dispensations or more over 12 months,
was identiﬁed in 1.6% and 1.5% of the UK and French children,
respectively. These percentages were slightly increased compared
with those in 2007, but the difference was not statistically
signiﬁcant (1.3% and 1.2%, respectively; P= 0.37 for France and
P= 0.19 for the United Kingdom). UK adults had higher levels of
inappropriate SABA use, both in 2007 and in 2013, than French
patients (Po0.0001 for both years). In 2007 and 2013, 8.6% and
10.5% of adult UK patients were exposed to inappropriate SABA
use, respectively. This was the case for 5.4% and 5.2% of French
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patients in 2007 and 2013, respectively (Figure 1). Overall, SABA
overuse in adults had increased in the United Kingdom
(Po0.001), although remaining stable in France (P= 0.67).
LABA inappropriate use. In 2013, inappropriate LABA use
occurred in 0.1% and 1.5% of UK and French adults, respectively.
This was a large reduction from 2007 UK and French ﬁgures of
0.4% and 2.6%, respectively (Po0.05 for both). Excessive use of
LABA relative to ICS (except ﬁxed-dose combination (FDC))
occurred in 0.2% of UK adults and in 0.7% of French adults in
2013. These percentages decreased from the 2007 ﬁgures of 0.6%
and 1.4% for United Kingdom (P= 0.29) and France (P= 0.003),
respectively (Figure 1), but the difference was statistically
signiﬁcant for the French ﬁgures only. Results in children showed
downward trends by time in both countries, although compared
with SABA overuse, LABA inappropriate use was more frequent in
French than in UK asthmatic children (Po0.0001).
Extrapolation to the whole UK and French populations
Altogether, in 2013, in the age group 6–40 years, the number of
UK and French patients at risk because of inappropriate asthma
management could be estimated at ~ 210,000 and 190,000,
respectively, overwhelmingly due to SABA overuse. In the United
Kingdom, SABA overuse increased between 2007 and 2013,
whereas it remained stable in France. On the contrary, inappropri-
ate use of LABA, both in France and in the United Kingdom,
declined considerably between 2007 and 2013 (Table 2; Figure 1).
DISCUSSION
Main ﬁndings
In this study analysing primary care data in 2007 and 2013, we
identiﬁed, both in the United Kingdom and France, numerous
patients inappropriately treated for their asthma, and therefore at
risk of adverse outcomes. Altogether, based on our ﬁgures and on
known asthma prevalence, it was estimated that in 2013 at least
210,000 and 190,000 patients were exposed to inappropriate
patterns of asthma therapy in the United Kingdom and France,
respectively, with a major concern regarding SABA overuse.
Indeed, in the United Kingdom, SABA overuse increased between
2007 and 2013 (12.1% of asthma patients), whereas it remained
stable in France (3.9%). Children were also overexposed to SABA,
with 1.2% in the United Kingdom and 1.5% in France with 12 or
more SABA units prescribed/dispensed per year.
Based on our study, extrapolating to the national population
suffering from asthma (within the 6–40-year age band only), in
2013 in the United Kingdom at least 7,000 asthma patients used
LABA inadequately. This was LABA use either with no ICS
co-therapy at all, or with periods of use of LABA as monotherapy,
a risk factor for severe asthma attacks and death.7 In France, the
situation was even more worrying, with 55,000 asthma patients
inappropriately exposed to LABA in 2013. Nonetheless, large
improvements were observed between 2007 and 2013 regarding
LABA use in both countries.
Interpretation of ﬁndings in relation to previously published work
Many studies have reported that regular use of SABA is associated
with increased airway hyper-responsiveness,8 mortality,9
healthcare utilisation10 and poor asthma control.11 Consequently,
current asthma treatment guidelines2 recommend using
quick-relief medications on an as-needed basis rather than as a
regularly scheduled medication. Despite these recommendations
and well-documented adverse consequences of excessive SABA
use, our data are in line with other studies suggesting that overuse
of SABA, misuse of LABA and underuse of ICS are common, and
they may compromise patient health.10,12
Table 1. Patients baseline characteristics
2007 2013
UK (N= 39,743) France (N= 4,910) UK (N=14,036) France (N= 5,657)
Mean age 23.7 (11.09) 22.1 (11.40) 24.2 (10.69) 21.4 (11.14)
Age groups (N, %)
Children (6–13 years) 10,776 (27.1%) 1,655 (33.7%) 3,138 (22.4%) 2,009 (35.5%)
Adults (14–40 years) 28,967 (72.9%) 3,255 (66.3%) 10,898 (77.6%) 3,648 (64.5%)
Males (N, %) 21,142 (53.2%) 2,494 (50.8%) 7,272 (51.8%) 2,916 (51.5%)
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Figure 1. Frequency (%) of inappropriate asthma therapy use in UK
and French patients during the 12-month follow-up. *P valueo0.05
when comparing 2007 versus 2013. #P valueo0.05 when comparing
UK versus France.
Table 2. Extrapolation of the number of subjects with inappropriate
asthma therapy use to the UK and French population (aged 6–40
years)
Extrapolations 2007 2013
UK France UK France
SABA overuse 158,560 139,650 206,040 136,150
LABA without ICS 7,040 68,600 2,720 38,500
LABA relative overuse
with respect to ICS use
11,520 38,500 4,760 17,150
Total 177,120 246,750 213,520 191,800
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist;
SABA, short-acting β2-agonist.
Inappropriate asthma therapy
M Belhassen et al
2
npj Primary Care Respiratory Medicine (2016) 16076 Published in partnership with Primary Care Respiratory Society UK
The safety of LABA remains controversial in asthma, particularly
in children, which led regulators to contraindicate LABA as a single
agent in asthma treatment from 2010.13 Recently updated meta-
analyses for formoterol and salmeterol failed to conclude concerns
on safety.7,14 Despite the absence of evidence of serious risk with
LABA associated with ICS in RCTs, likely due to infrequent
occurrence of many events, the precision of results was low.
Evidence is also limited in the observational context.
Consequently, the Food and Drug Administration issued in 2010
a ‘Dear Doctor Letter’ to warn of the risks associated with
prescribing LABA alone for asthma.15 The improvements in LABA
use observed in both countries may be the consequence of such
regulatory warnings. Part of LABA use in monotherapy could also
be due to the prevention of exercise-induced asthma.16 However,
as such instances are rare, the overwhelming majority of
LABA users should use ICS simultaneously (i.e., in ﬁxed-dose
combinations).
Strengths and limitations of this study
This study is important as it explores inappropriate patterns of
asthma therapy use in longitudinal data sets comprising large
numbers of patients. These data sets exhaustively record all
therapies prescribed or dispensed. A limitation in the use of claims
data was, however, the absence of disease diagnostic codes in
France, so that asthma patients were identiﬁed using an algorithm
(age criteria and dispensations). However, based on this algorithm,
our asthma prevalence data were comparable to the data from
other studies.17,18 By contrast, in the United Kingdom, asthma
patients were diagnosed using a physician-diagnostic code.19,20
Quality of asthma diagnosis may however be debatable in the
primary care setting in the absence of referral to a specialist, and
over-diagnosis and misdiagnosis of asthma are a possibility.2,21
In our study, additional precautions were taken to include
patients likely to suffer from asthma, including the requirement of
at least three dispensations of R03 over 12 months in a prior
period. In addition, children aged o6 years, adults 440 years
(to avoid including chronic obstructive pulmonary disease (COPD))
and patients with cystic ﬁbrosis were excluded. Consequently, our
study was completed with cohorts that were highly likely to
include only asthma patients.
Two different data sets were used, one recording prescribing
and the other recording dispensations. Unﬁlled prescriptions are
not recorded in French claims data, and there was no way to verify
whether inadequate use was primarily due to patients or to
healthcare professionals. However, one of our recent studies has
shown that inappropriate management by general practitioners is
not uncommon in France or in the UK.22
No outcome data (e.g., deaths and hospitalisations) were
computed, as the purpose of this research was to give an
overview of the extent of inappropriate management of asthma.
Outcome data will be collected in the context of the ASTROLAB
study that relates detailed patterns of use of asthma therapy to
outcomes.23
Another issue raised by the UK National Review of Asthma
Deaths was the underuse of ICS. In this study, underuse of ICS was
not investigated, as unlike overuse of SABA and use of LABA
without ICS, this exposure is difﬁcult to assess in isolation from the
clinical context. Beyond the complex issue of adherence,24 many
subjects have seasonal symptoms leading to temporary ICS use. In
the absence of detailed clinical data and within our observational
study design, it is almost impossible to distinguish persistent
asthma, in need of regular ICS therapy, from milder or intermittent
asthma, at lower risk of exacerbations.
Implications for future research, policy and practice
The prevalence of inappropriate patterns of use of asthma therapy
was high, particularly regarding the overuse of SABA. The estimate
was higher in the United Kingdom, possibly due to the insufﬁcient
priority given to respiratory diseases in the United Kingdom.25
Inappropriate LABA use confers considerable risk, both for
patients exposed to LABA only, and for patients with at least
twice higher use of LABA than of single ICS.
Clinicians could improve the quality of prescribing,22 and
patients should be trained regarding appropriate use of
therapy24 and technical use of inhalers.26 Clinicians should be
informed of the actual exposure of their patients, e.g., via feedback
from claims data or from consulting practice prescribing records.
Personal action plans should be written, describing how patients
may recognise a deterioration in their asthma and what steps they
should take to re-establish control.2 In the United Kingdom,
SIMPLES is a structured primary care approach to the structured
review of patients with partly controlled or uncontrolled asthma,
which encompasses patient education monitoring, lifestyle and
pharmacological management while addressing support needs.27
The SIMPLES approach, used iteratively, should be able to identify
those patients who might beneﬁt from referral to a specialist
for further assessment avoiding inappropriate escalation of
treatment. Other clinical healthcare professionals (e.g., nurses)
could also review the use of therapy, and provide training and
support to patients.28
Policymakers should develop actions targeting both clinicians
(asthma audits) and patients (e.g., providing ways for patients to
have direct contacts with advisors, e.g., using IT, or through
pharmacies). In the United Kingdom, from their electronic medical
records, general practitioners can easily access the list of
prescribed asthma treatments, enabling identiﬁcation of those
who should be invited to attend for regular reviews. A similar
approach could improve the quality of asthma management in
France.
Conclusions
Concomitant outcome data would be useful to illustrate the
potential impact of inappropriate management in asthma, and to
assess the quality of care in large asthma populations. Other
markers of quality of care and predictors of subsequent asthma
exacerbation should not be overlooked (e.g., low therapeutic ratio
controller-to-total asthma drug ratio or ICS-to-total asthma drug
ratio (o50%)).29
This study might be replicated targeting populations at
high risk, such as patients who experienced near-fatal asthma,
or more generally those who have experienced asthma-related
hospitalisation, or used several courses of oral corticosteroids
over 1 year.
Using similar methods, the study might be conducted in other
European countries, to identify inappropriate patterns of use and
to improve the care of asthma.
Holistic interventions on general practitioners and on patients’
behaviours might be also conducted.30 Systematic targeting of
education and skills training in primary care have demonstrated
the ability to make signiﬁcant impact on patient outcomes.31
Finally, omics and other system approaches within existing
projects32 might be considered.
We conclude that both in the United Kingdom and France,
despite noticeable differences in healthcare systems, inappropri-
ate asthma therapy is a frequent ﬁnding that improved little
during the past decade. Therefore, concerns are raised about the
current delivery of asthma care, as individual patients are exposed
to potentially serious, but preventable, outcomes. Corrective
measures including educational interventions, and close monitor-
ing at the population level, are deemed necessary to reduce the
asthma-associated burden.
Inappropriate asthma therapy
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MATERIALS AND METHODS
Setting
Parallel population-based cohorts were created in each country for two
distinct periods: 2007 and 2013. The Optimum Patient Care Research
Database (OPCRD) electronic health records database in the United
Kingdom and the Permanent Beneﬁciaries Sample database (EGB) in
France were used.
The OPCRD comprises routinely recorded clinical data extracted through
the Optimum Patient Care Clinical Service Evaluation. The service extracts
data from 600 practices spread throughout the United Kingdom, and
collects all longitudinal data from these practices. As new practices are
being recruited and contribute data from past years, this database resulted
in a higher data collection from 2007 versus 2013. The database
(anonymised) is comprised of electronic medical records and characterises
patients in terms of their demography, disease control and exacerbation
history.33
The EGB database is a 1/97th representative random sample of the
Système National d'Information Inter-Régimes de l'Assurance Maladie
(SNIIR-AM). The SNIIR-AM34 is a French nation-wide, population-based
database that records anonymised individual data on all reimbursements
for healthcare utilisation, including therapy. There is no information on the
medical condition linked to reimbursements.
Selection criteria
Patients with asthma were selected in both countries, for the years 2007
and 2013. Given the differences between the database sources used,
notably regarding the availability of recorded diagnoses, speciﬁc inclusion
criteria were used for each country, to allow comparison. In the United
Kingdom, patients with a diagnosis of asthma in 2007, plus at least three
prescriptions of respiratory drugs (SABAs, LABAs, ICS, ﬁxed-dose combina-
tion of ICS and LABAs, leukotriene receptor antagonist and xanthines) at
three different dates (entry date =date of third prescription), and aged
6–40 years at entry date were selected.
French patients with at least three dispensations of respiratory drugs
(SABAs, LABAs, ICS, ﬁxed-dose combination of ICS and LABAs, leukotriene
receptor antagonist and xanthines) in 2007 at three different dates were
qualiﬁed to enter the cohort (entry date = date of the third dispensation).
Patients aged 6–40 years at entry date were selected. An upper age limit of
40 was selected to avoid including patients with COPD or other age-related
respiratory conditions.
The same exclusion criteria were used for both countries during the
12 months before entry date, namely: any dispensation/prescription of
omalizumab, chronic use of oral corticosteroids (deﬁned as 44 prescrip-
tions of oral steroids at ⩾ 4 different dates over 12 months preceding entry
date in the UK OPCRD, and as ⩾ 4 different dates of dispensation of oral
steroids over 12 months at ⩾ 2 different quarters in French EGB), the
presence of a diagnosis of COPD or prescribing/dispensation of tiotropium
or indacaterol alone, cystic ﬁbrosis, lung cancer, bronchiectasis, tubercu-
losis or sarcoidosis. Patients with o12 months of follow-up as of entry
date were also discarded. In France, exclusion criteria were obtained from
long-term condition (LTC) status and/or hospital admission (diagnoses in
ICD-10 codes) and on Anatomical Therapeutic Chemical codes. In the
United Kingdom, exclusion criteria were assessed from Read codes based
on physician diagnoses35 (Appendix available upon request to the
authors).
End points
The occurrence of three inappropriate patterns of use of asthma therapy
was assessed during the study period:
1. Overuse of SABAs, deﬁned as 12 units or more over 12 months,
2. Inappropriate (off-label) LABA use, deﬁned as:
a. Either LABA without ICS (single ICS or in ﬁxed-dose combination
LABA+ICS).
b. Or unbalanced use of LABA with respect to ICS use, deﬁned as at
least twice as many units of LABA prescribed/dispensed than units
of single ICS (e.g., ratio LABA/ICS⩾ 2).
Treatment units consisted of prescribed/dispensed packs.
Statistical analysis
Parallel analyses were conducted for both 2007 and 2013 cohorts.
Analyses were stratiﬁed by age groups: children (6–13 years) and adults
(14–40 years).
Patients were preliminarily described according to baseline character-
istics at cohort entry.
In each country, patients’ characteristics and inappropriate patterns
were described in 2007 and 2013 cohorts. The British and French 2013
cohorts were compared as to the percentages of patients presenting each
criterion during the study period.
Finally, an extrapolation of asthma burden was estimated in the general
population via direct standardisation.36 For the United Kingdom,
extrapolations were computed by applying the prevalence of asthma
(computed from Quality Outcome Framework recorded prevalence) in the
entire UK population for the given year to the number of UK subjects
within the 6–40-year age band (taken from the Ofﬁce for National
Statistics).37 Extrapolations to the overall French asthma population aged
6–40 years were computed based on the representativeness of the EGB,
i.e., random sample of the French population38 and the prevalence of
asthma in patients aged 6–40 years.17
Quantitative variables were described using descriptive statistics: means
and s.d.’s, and qualitative variables with counts and percentages.
Comparative statistics were conducted with Mann–Whitney tests for
continuous variables, and Χ2-tests for percentages. Statistical signiﬁcance
was considered at P valueo0.05.
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